PuraCath Medical Shows Greater Than 99.99% Reduction in ‘Superbug’ Candida Auris with One Second of UVC Exposure

puracath • Jun 19, 2019

JUNE 18, 2019

PuraCath Medical, a venture-backed medical device company based in Silicon Valley, announced today that it has achieved 99.99% disinfection on its vascular access Firefly disinfection technology system with Candida auris (‘superbug’), Staphylococcus aureus, and Candida albicans.

“Achieving greater than 4 log disinfection in these virulent microbes with only one second of UV exposure is an incredible breakthrough and will help with compliance and ease of disinfection whenever accessing vascular access devices (VAD) and infusion systems!” says Dr. Gregory Schears, Professor of Anesthesiology in Rochester, MN. “Inadequate disinfection of needleless connectors is a significant contributor to biofilm formation in VADs and hence the development of CRBSIs. These results suggest that the Firefly disinfection technology may have a huge impact in helping to reduce CRBSIs in hospitals. This is very exciting!”

In vitro testing of the Firefly disinfection technology demonstrated the effectiveness of the UV light-based vascular access catheter connection system in achieving a greater than 4 log reduction of several microorganisms known to cause a Catheter Line Associated Bloodstream Infection (CLABSI). The mean log reduction of these microorganisms was 4.44 +/- 0.22 for Candida auris, 5.06 +/- 0.62 for Candida albicans, and 5.70 +/- 0.62 for Staphylococcus aureus.

“Our team is thrilled to have achieved this big scientific breakthrough of achieving 99.99% reduction in just one second of UV-C light,” says PuraCath Medical Chief Executive Officer and Co-Founder, Ms. Julia Rasooly. “With a device that is now faster than any other disinfection platform out there and safer, we look forward to having Firefly be the standard of care for catheter line disinfection in all hospitals and outpatient units.”

What is vascular access? 
Vascular access refers to a rapid, direct method of introducing or removing devices or medication into the bloodstream. The global vascular access device market is valued at $3.6B and expected to grow at a CAGR of 6.89% per year. The vascular access market is comprised of peripheral IV catheters (PIVCs), peripherally inserted central catheters (PICCs), central venous catheters (CVCs), and implantable ports. Infections related to these catheters are named Catheter Related Bloodstream Infections (CRBSIs).

PuraCath Medical Receives 510(k) Clearance for its Needleless Connector for Vascular Access
By puracath 03 Aug, 2021
Device is intended for use primarily by ICU nurses during infusions in patients in a critical care setting. PuraCath Medical™, a venture-backed startup company focusing on the development of technologies to reduce infections in patients with intravascular catheters, announced today that it has received 510(k) clearance for its FireFly™ Needleless Connector from the U.S. Food […]
Why We Aren’t Using UV to Disinfect Everything—Yet
By puracath 16 Jun, 2020
Negative perception and costs pose obstacles to a promising technology As the coronavirus pandemic continues, a technology that has existed for over 100 years is getting renewed attention as a promising disinfection tool. Ultraviolet germicidal radiation, which uses short-wavelength UV rays to kill bacteria and viruses, is already used to disinfect the air, water, and […]
PuraCath UV Device Displays a 99.9999% Disinfection of COVID-19 Virus in 1 Second
By puracath 27 Apr, 2020
PuraCath has been partnered and working with a top tier BSL-3 National Laboratory, which has a premiere high containment infectious disease facilities to test its Firefly UV device for the ICU and hospitals with 2019-nCoV (the COVID-19 virus). The preliminary results show that PuraCath’s device has achieved 99.9999% disinfection with SARS-CoV-2 (the virus that is […]
PuraCath FireflyTM Can Kill Deadly Microorganisms with UV Light, Like SARS CoV-2
By puracath 19 Mar, 2020
President Trump has officially declared a national emergency. A novel coronavirus has been identified in Wuhan City, China and has spread worldwide. It has been named SARS CoV-2 (causing disease COVID-19) by WHO. SARS CoV-2 has officially become a global pandemic by WHO. There have already been over 170,000 confirmed cases to date with an […]
By puracath 07 Mar, 2017
San Francisco, California (March 7, 2017) – PuraCath Medical has published the result of its recent research on its ultraviolet (UV) light-based peritoneal dialysis catheter connection system in Peritoneal Dialysis International (PDI), the official Journal of the International Society for Peritoneal Dialysis. PDI is a major source of knowledge in the field of peritoneal dialysis and aims […]
PuraCath Medical to Present Data on FireFly™ Peritoneal Dialysis Connector Disinfecting System durin
By Larry Yost 12 May, 2016
San Francisco, California (May 12, 2016) – Data being presented will support planned introduction of PuraCath Medical’s technology in the European Union. PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it will present data on its next generation version of the FireFly™ […]
PuraCath Medical Presents Data at National Kidney Foundation 2016 Spring Clinical Meetings
By Larry Yost 28 Apr, 2016
Boston, Massachusetts (April 28, 2016) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it presented data on its next generation version of the FireFly™ Peritoneal Dialysis (PD) Connector Disinfecting System during the National Kidney Foundation’s 2016 Spring Clinical Meetings held […]
PuraCath Medical Presents New Research Data during 36th Annual Dialysis Conference
By Larry Yost 29 Feb, 2016
Company presents study on the effectiveness of next-generation version of the FireFly™ Peritoneal Dialysis Connector Disinfecting System Seattle, Washington (February 29, 2016) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it presented data on its next generation version of […]
PuraCath Medical Receives 510(k) Clearance for the FireFly™ Peritoneal Dialysis Connector Disinfecti
By puracath 26 Jan, 2016
PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it has received 510(k) clearance for its FireFly™ Peritoneal Dialysis Connector Disinfecting System from the U.S. Food and Drug Administration (FDA). This regulatory determination by the FDA gives PuraCath clearance to market […]
By puracath 22 Oct, 2015
We are excited to announce that PuraCath Medical is listed as a start-up to watch in the latest volume of the MedTech Strategist published on October 16th.  Please read the full article here.
More Posts
Share by: